AAAAAA

   
Results: 1-16 |
Results: 16
PHARMACOLOGICAL CHARACTERIZATION OF MDL-105,519, AN NMDA RECEPTOR GLYCINE SITE ANTAGONIST
Authors: BARON BM HARRISON BL KEHNE JH SCHMIDT CJ VANGIERSBERGEN PLM WHITE HS SIEGEL BW SENYAH Y MCCLOSKEY TC FADAYEL GM TAYLOR VL MURAWSKY MK NYCE P SALITURO FG
Citation: Bm. Baron et al., PHARMACOLOGICAL CHARACTERIZATION OF MDL-105,519, AN NMDA RECEPTOR GLYCINE SITE ANTAGONIST, European journal of pharmacology, 323(2-3), 1997, pp. 181-192
THE RECEPTOR-BINDING PROFILE OF MDL-100,907
Authors: VANGIERSBERGEN PLM BARON BM ELANDS J JOHNSON MP SORENSEN SM
Citation: Plm. Vangiersbergen et al., THE RECEPTOR-BINDING PROFILE OF MDL-100,907, Schizophrenia research, 18(2-3), 1996, pp. 4-4
PRECLINICAL PROFILE OF MDL-100907, A POTENT AND SELECTIVE 5-HT2A ANTAGONIST IN DEVELOPMENT FOR SCHIZOPHRENIA
Authors: SORENSEN SM CARR AA VANGIERSBERGEN PLM HITCHCOCK JM KEHNE JH SCHMIDT CJ
Citation: Sm. Sorensen et al., PRECLINICAL PROFILE OF MDL-100907, A POTENT AND SELECTIVE 5-HT2A ANTAGONIST IN DEVELOPMENT FOR SCHIZOPHRENIA, Schizophrenia research, 18(2-3), 1996, pp. 13-13
IN-VITRO AND IN-VIVO CHARACTERIZATION OF MDL-105,212A, A NONPEPTIDE NK-1 NK-2 TACHYKININ RECEPTOR ANTAGONIST/
Authors: KUDLACZ EM SHATZER SA KNIPPENBERG RW LOGAN DE POIROT M VANGIERSBERGEN PLM BURKHOLDER TP
Citation: Em. Kudlacz et al., IN-VITRO AND IN-VIVO CHARACTERIZATION OF MDL-105,212A, A NONPEPTIDE NK-1 NK-2 TACHYKININ RECEPTOR ANTAGONIST/, The Journal of pharmacology and experimental therapeutics, 277(2), 1996, pp. 840-851
PRECLINICAL CHARACTERIZATION OF THE POTENTIAL OF THE PUTATIVE ATYPICAL ANTIPSYCHOTIC MDL-100,907 AS A POTENT 5-HT2A ANTAGONIST WITH A FAVORABLE CNS SAFETY PROFILE
Authors: KEHNE JH BARON BM CARR AA CHANEY SF ELANDS J FELDMAN DJ FRANK RA VANGIERSBERGEN PLM MCCLOSKEY TC JOHNSON MP MCCARTY DR POIROT M SENYAH Y SIEGEL BW WIDMAIER C
Citation: Jh. Kehne et al., PRECLINICAL CHARACTERIZATION OF THE POTENTIAL OF THE PUTATIVE ATYPICAL ANTIPSYCHOTIC MDL-100,907 AS A POTENT 5-HT2A ANTAGONIST WITH A FAVORABLE CNS SAFETY PROFILE, The Journal of pharmacology and experimental therapeutics, 277(2), 1996, pp. 968-981
MODULATION OF AGONIST BINDING BY GUANINE-NUCLEOTIDES IN CHO CELLS EXPRESSING MUSCARINIC M1-M5 RECEPTORS
Authors: VANGIERSBERGEN PLM LEPPIK R
Citation: Plm. Vangiersbergen et R. Leppik, MODULATION OF AGONIST BINDING BY GUANINE-NUCLEOTIDES IN CHO CELLS EXPRESSING MUSCARINIC M1-M5 RECEPTORS, Naunyn-Schmiedeberg's archives of pharmacology, 352(2), 1995, pp. 166-172
DIFFERENCES IN AGONIST POTENCY RATIOS AT HUMAN M1 MUSCARINIC RECEPTORS EXPRESSED IN A9L AND CHO CELLS
Authors: RICHARDS MH VANGIERSBERGEN PLM
Citation: Mh. Richards et Plm. Vangiersbergen, DIFFERENCES IN AGONIST POTENCY RATIOS AT HUMAN M1 MUSCARINIC RECEPTORS EXPRESSED IN A9L AND CHO CELLS, Life sciences, 57(4), 1995, pp. 397-402
SYNTHESIS AND BIOLOGICAL EVALUATION OF MDL-74,019DG, A CENTRALLY ACTIVE M(1) VERSUS M(2) SELECTIVE MUSCARINIC RECEPTOR ANTAGONIST
Authors: VANHIJFTE L ZERR V HIBERT M MARCINIAK G MOSER P MORAN P RICHARDS MH VANGIERSBERGEN PLM
Citation: L. Vanhijfte et al., SYNTHESIS AND BIOLOGICAL EVALUATION OF MDL-74,019DG, A CENTRALLY ACTIVE M(1) VERSUS M(2) SELECTIVE MUSCARINIC RECEPTOR ANTAGONIST, Life sciences, 56(11-12), 1995, pp. 1013-1013
MDL-100,458 AND MDL-102,288 - 2 POTENT AND SELECTIVE GLYCINE RECEPTORANTAGONISTS WITH DIFFERENT FUNCTIONAL PROFILES
Authors: KEHNE JH BARON BM HARRISON BL MCCLOSKEY TC PALFREYMAN MG POIROT M SALITURO FG SIEGEL BW SLONE AL VANGIERSBERGEN PLM WHITE HS
Citation: Jh. Kehne et al., MDL-100,458 AND MDL-102,288 - 2 POTENT AND SELECTIVE GLYCINE RECEPTORANTAGONISTS WITH DIFFERENT FUNCTIONAL PROFILES, European journal of pharmacology, 284(1-2), 1995, pp. 109-118
MUSCARINIC TOXINS FROM THE BLACK MAMBA DENDROASPIS-POLYLEPIS
Authors: JOLKKONEN M VANGIERSBERGEN PLM HELLMAN U WERNSTEDT C ORAS A SATYAPAN N ADEM A KARLSSON E
Citation: M. Jolkkonen et al., MUSCARINIC TOXINS FROM THE BLACK MAMBA DENDROASPIS-POLYLEPIS, European journal of biochemistry, 234(2), 1995, pp. 579-585
HUMAN MUSCARINIC RECEPTORS EXPRESSED IN A9L AND CHO CELLS - ACTIVATION BY FULL AND PARTIAL AGONISTS
Authors: RICHARDS MH VANGIERSBERGEN PLM
Citation: Mh. Richards et Plm. Vangiersbergen, HUMAN MUSCARINIC RECEPTORS EXPRESSED IN A9L AND CHO CELLS - ACTIVATION BY FULL AND PARTIAL AGONISTS, British Journal of Pharmacology, 114(6), 1995, pp. 1241-1249
CHARACTERIZATION OF MDL 74,019, A M1 VS M2 SELECTIVE MUSCARINIC RECEPTOR ANTAGONIST
Authors: SECREST RJ RICHARDS MH VANGIERSBERGEN PLM MOSER PC VANHIJFTE LE LARISON ED MONACO FJ ZERR VO
Citation: Rj. Secrest et al., CHARACTERIZATION OF MDL 74,019, A M1 VS M2 SELECTIVE MUSCARINIC RECEPTOR ANTAGONIST, The FASEB journal, 8(5), 1994, pp. 10000875-10000875
THE RECEPTORS FOR ENDOTHELINS AND THEIR ANALOGS IN SK-N-MC NEUROBLASTOMA-CELLS
Authors: HUGGINS JP PELTON JT VANGIERSBERGEN PLM
Citation: Jp. Huggins et al., THE RECEPTORS FOR ENDOTHELINS AND THEIR ANALOGS IN SK-N-MC NEUROBLASTOMA-CELLS, Peptides, 15(3), 1994, pp. 529-536
A TOXIN FROM THE GREEN MAMBA DENDROASPIS-ANGUSTICEPS - AMINO-ACID-SEQUENCE AND SELECTIVITY FOR MUSCARINIC M4 RECEPTORS
Authors: JOLKKONEN M VANGIERSBERGEN PLM HELLMAN U WERNSTEDT C KARLSSON E
Citation: M. Jolkkonen et al., A TOXIN FROM THE GREEN MAMBA DENDROASPIS-ANGUSTICEPS - AMINO-ACID-SEQUENCE AND SELECTIVITY FOR MUSCARINIC M4 RECEPTORS, FEBS letters, 352(1), 1994, pp. 91-94
THE NIGROSTRIATAL DOPAMINE SYSTEM - ROLE IN THE DEVELOPMENT OF HYPERTENSION IN SPONTANEOUSLY HYPERTENSIVE RATS
Authors: LINTHORST ACE VANGIERSBERGEN PLM GRAS M VERSTEEG DHG DEJONG W
Citation: Ace. Linthorst et al., THE NIGROSTRIATAL DOPAMINE SYSTEM - ROLE IN THE DEVELOPMENT OF HYPERTENSION IN SPONTANEOUSLY HYPERTENSIVE RATS, Brain research, 639(2), 1994, pp. 261-268
SK-N-MC CELLS BIND AND RESPOND TO ENDOTHELINS AND ANALOGS - PEPTIDE CONFORMATION AND MODELING OF RESPONSES
Authors: HUGGINS JP PELTON JT VANGIERSBERGEN PLM
Citation: Jp. Huggins et al., SK-N-MC CELLS BIND AND RESPOND TO ENDOTHELINS AND ANALOGS - PEPTIDE CONFORMATION AND MODELING OF RESPONSES, Journal of neurochemistry, 61, 1993, pp. 190000084-190000084
Risultati: 1-16 |